Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe

  Multiple Sclerosis

  Free Subscription

Articles published in Ann Neurol

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    May 2020
  1. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    PubMed     Abstract available

  2. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    PubMed     Abstract available

  3. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.

    April 2020
  4. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.

  5. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    PubMed     Abstract available

  6. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    PubMed     Abstract available

  7. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    PubMed     Abstract available

  8. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    PubMed     Abstract available

    March 2020
  9. DE MOL CL, Jansen PR, Muetzel RL, Knol MJ, et al
    Polygenic multiple sclerosis risk and population-based childhood brain imaging.
    Ann Neurol. 2020 Mar 12. doi: 10.1002/ana.25717.
    PubMed     Abstract available

    February 2020
  10. OUELLETTE R, Mangeat G, Polyak I, Warntjes M, et al
    Validation of rapid magnetic resonance myelin imaging in multiple sclerosis.
    Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705.
    PubMed     Abstract available

    January 2020
  11. OLDONI E, Smets I, Mallants K, Vandebergh M, et al
    CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity.
    Ann Neurol. 2020 Jan 29. doi: 10.1002/ana.25691.
    PubMed     Abstract available

  12. DOBSON R, Jitlal M, Marshall CR, Noyce AJ, et al
    Ethnic and socioeconomic associations with multiple sclerosis risk.
    Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688.
    PubMed     Abstract available

  13. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    PubMed     Abstract available

    November 2019
  14. CHUNG KK, Altmann D, Barkhof F, Miszkiel K, et al
    A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes.
    Ann Neurol. 2019 Nov 6. doi: 10.1002/ana.25637.
    PubMed     Abstract available

    September 2019
  15. KRYSKO KM, Henry RG, Cree BAC, Lin J, et al
    Telomere length is associated with disability progression in multiple sclerosis.
    Ann Neurol. 2019 Sep 4. doi: 10.1002/ana.25592.
    PubMed     Abstract available

    August 2019
  16. MOCCIA M, Prados F, Filippi M, Rocca MA, et al
    Longitudinal spinal cord atrophy in multiple sclerosis using the generalised boundary shift integral.
    Ann Neurol. 2019 Aug 6. doi: 10.1002/ana.25571.
    PubMed     Abstract available

  17. LOONSTRA FC, Verberk IMW, Wijburg MT, Wattjes MP, et al
    Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Ann Neurol. 2019;86:322-324.

  18. DALLA COSTA G, Martinelli V, Furlan R, Comi G, et al
    Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Ann Neurol. 2019;86:324.

    June 2019
  19. GIL-PEROTIN S, Alcala C, Perez-Miralles FC, Casanova B, et al
    Silent progression or bout-onset progressive multiple sclerosis?
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25537.

  20. CREE BAC, Hauser SL
    Reply to "Silent progression or bout-onset progressive multiple sclerosis?"
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25536.

  21. MUNGER KL, Hongell K, Cortese M, Aivo J, et al
    Epstein-Barr virus and multiple sclerosis risk in the Finnish Maternity Cohort.
    Ann Neurol. 2019 Jun 21. doi: 10.1002/ana.25532.
    PubMed     Abstract available

    May 2019
  22. VAN LANGELAAR J, Rijvers L, Janssen M, Wierenga-Wolf AF, et al
    Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.
    Ann Neurol. 2019 May 28. doi: 10.1002/ana.25508.
    PubMed     Abstract available

  23. NOLAN-KENNEY RC, Liu M, Akhand O, Calabresi PA, et al
    Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
    Ann Neurol. 2019;85:618-629.
    PubMed     Abstract available

    March 2019
  24. AKTAS O, Hartung HP
    CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.
    Ann Neurol. 2019 Mar 22. doi: 10.1002/ana.25471.

  25. CREE BAC, Hollenbach JA, Bove R, Kirkish G, et al
    Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis.
    Ann Neurol. 2019 Mar 9. doi: 10.1002/ana.25463.
    PubMed     Abstract available

    February 2019
  26. DALLA COSTA G, Martinelli V, Moiola L, Sangalli F, et al
    Serum neurofilaments increase at PML onset in natalizumab-treated MS patients.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25437.
    PubMed     Abstract available

  27. FADDA G, Brown RA, Magliozzi R, Aubert-Broche B, et al
    A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.
    Ann Neurol. 2019 Feb 4. doi: 10.1002/ana.25429.
    PubMed     Abstract available

    January 2019
  28. BAERT L, Benkhoucha M, Popa N, Ahmed MC, et al
    APRIL-mediated anti-inflammatory response of astrocytes in multiple sclerosis.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25415.
    PubMed     Abstract available

  29. CACCIAGUERRA L, Meani A, Mesaros S, Radaelli M, et al
    Brain and cord imaging features in neuromyelitis optica spectrum disorders.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411.
    PubMed     Abstract available

    October 2018
  30. BEVAN RJ, Evans R, Griffiths L, Watkins LM, et al
    Ann Neurol. 2018 Oct 25. doi: 10.1002/ana.25365.
    PubMed     Abstract available

    August 2018
  31. WOLINSKY JS, Montalban X, Hauser SL, Giovannoni G, et al
    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Ann Neurol. 2018 Aug 29. doi: 10.1002/ana.25313.
    PubMed     Abstract available

    June 2018
  32. JIA X, Madireddy L, Caillier S, Santaniello A, et al
    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
    Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25263.
    PubMed     Abstract available

    May 2018
  33. DISANTO G, Zecca C, MacLachlan S, Sacco R, et al
    Prodromal symptoms of multiple sclerosis in primary care.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25247.
    PubMed     Abstract available

    April 2018
  34. TANKOU SK, Regev K, Healy BC, Tjon E, et al
    A probiotic modulates the microbiome and immunity in multiple sclerosis.
    Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
    PubMed     Abstract available

    March 2018
  35. CRAMER SP, Simonsen HJ, Varatharaj A, Galea I, et al
    Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
    Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25219.
    PubMed     Abstract available

  36. ANTEL J
    The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.

  37. COLES A
    Authorship of phase 3 trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25203.

  38. MAGLIOZZI R, Howell OW, Nicholas R, Cruciani C, et al
    Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25197.
    PubMed     Abstract available

    February 2018
  39. BECK ES, Reich DS
    Brain atrophy in multiple sclerosis: How deep must we go?
    Ann Neurol. 2018;83:208-209.

  40. MAGGI P, Absinta M, Grammatico M, Vuolo L, et al
    Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.
    Ann Neurol. 2018;83:283-294.
    PubMed     Abstract available

    January 2018
  41. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
    Deep grey matter volume loss drives disability worsening in multiple sclerosis.
    Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
    PubMed     Abstract available

  42. AZEVEDO CJ, Cen SY, Khadka S, Liu S, et al
    Thalamic Atrophy in MS: An MRI Marker of Neurodegeneration Throughout Disease.
    Ann Neurol. 2018 Jan 12. doi: 10.1002/ana.25150.
    PubMed     Abstract available

    December 2017
  43. GILES DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, et al
    Myeloid cell plasticity in the evolution of central nervous system autoimmunity.
    Ann Neurol. 2017 Dec 28. doi: 10.1002/ana.25128.
    PubMed     Abstract available

  44. GREENFIELD AL, Hauser SL
    B Cell Therapy for Multiple Sclerosis: Entering an Era.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25119.
    PubMed     Abstract available

    October 2017
  45. BARBOUR C, Kosa P, Komori M, Tanigawa M, et al
    Molecular-based diagnosis of Multiple Sclerosis and its progressive stage.
    Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25083.
    PubMed     Abstract available

  46. AZODI S, Nair G, Enose-Akahata Y, Charlip E, et al
    Imaging Spinal Cord Atrophy in Progressive Myelopathies: HTLV-I Associated Neurologic Disease (HAM/TSP) and Multiple Sclerosis (MS).
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25072.
    PubMed     Abstract available

  47. JENDE JME, Hauck GH, Diem R, Weiler M, et al
    Peripheral nerve involvement in multiple sclerosis Demonstration by magnetic resonance neurography.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25068.
    PubMed     Abstract available

  48. MAINERO C, Louapre C
    Unravelling cortical pathology in multiple sclerosis using the T1-/T2-weighted ratio?
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25063.

  49. WIJNANDS JMA, Tremlett H
    Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25061.

  50. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Reply to: Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25062.

    September 2017
  51. FITZGERALD KC, Munger KL, Ascherio A
    Reply to "Stratified analyses are necessary to verify the influence of salt intake in multiple sclerosis".
    Ann Neurol. 2017 Sep 29. doi: 10.1002/ana.25055.

  52. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Concussion in adolescence and risk of multiple sclerosis.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25036.
    PubMed     Abstract available

  53. ZAHEDNASAB H, Harirchian MH, Karampoor S, Keyvani H, et al
    MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25037.

  54. FISSOLO N, Pignolet B, Brassat D, Comabella M, et al
    Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25039.

    August 2017
  55. NAKAMURA K, Chen JT, Ontaneda D, Fox RJ, et al
    T1-/T2-weighted ratio differs in demyelinated cortex of multiple sclerosis.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25019.
    PubMed     Abstract available

  56. RIGHART R, Biberacher V, Jonkman LE, Klaver R, et al
    Cortical pathology in MS detected by the T1/T2-weighted ratio from routine MRI.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25020.
    PubMed     Abstract available

    July 2017
  57. YATES RL, Esiri MM, Palace J, Jacobs B, et al
    Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
    Ann Neurol. 2017 Jul 18. doi: 10.1002/ana.24997.
    PubMed     Abstract available

  58. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
    MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
    Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
    PubMed     Abstract available

    May 2017
  59. FITZGERALD KC, Munger KL, Hartung HP, Freedman MS, et al
    Sodium intake and multiple sclerosis activity and progression in BENEFIT.
    Ann Neurol. 2017 May 26. doi: 10.1002/ana.24965.
    PubMed     Abstract available

  60. DISANTO G, Barro C, Benkert P, Naegelin Y, et al
    Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Ann Neurol. 2017 May 16. doi: 10.1002/ana.24954.
    PubMed     Abstract available

  61. CUI QL, Khan D, Rone M, Rao V, et al
    Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
    Ann Neurol. 2017 May 3. doi: 10.1002/ana.24944.
    PubMed     Abstract available

  62. IAFFALDANO P, Simone M, Lucisano G, Ghezzi A, et al
    Prognostic indicators in pediatric clinically isolated syndrome.
    Ann Neurol. 2017;81:729-739.
    PubMed     Abstract available

    April 2017
  63. ANDRODIAS G, Bernard E, Biotti D, Collongues N, et al
    Multiple sclerosis broke my heart.
    Ann Neurol. 2017 Apr 24. doi: 10.1002/ana.24935.
    PubMed     Abstract available

  64. SELMAJ I, Cichalewska M, Namiecinska M, Galazka G, et al
    Global Exosome Transcriptome Profiling Reveals Biomarkers for Multiple Sclerosis.
    Ann Neurol. 2017 Apr 15. doi: 10.1002/ana.24931.
    PubMed     Abstract available

    December 2016
  65. HERRANZ E, Hooker JM, Izquierdo-Garcia D, Loggia ML, et al
    11 C-PBR28 increase in multiple sclerosis reflects neuroinflammation.
    Ann Neurol. 2016 Dec 29. doi: 10.1002/ana.24865.

  66. RAFFEL J, Sridharan S, Nicholas R
    [11 C]PBR-28 PET in multiple sclerosis: Neuroinflammation or otherwise?
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24853.

    October 2016
  67. GOBEL K, Kraft P, Pankratz S, Gross CC, et al
    Prothrombin and factor X are elevated in multiple sclerosis patients.
    Ann Neurol. 2016 Oct 24. doi: 10.1002/ana.24807.
    PubMed     Abstract available

    September 2016
  68. HERRANZ E, Gianni C, Louapre C, Treaba CA, et al
    The neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Ann Neurol. 2016 Sep 30. doi: 10.1002/ana.24791.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.